Bayer’s 72% Surge Enters a Defining Stretch as Barclays Lifts Target and Operational Focus Sharpens

Bayer shares climb 72% after Supreme Court ruling weakens glyphosate claims; Barclays raises target to €60, but August 4 earnings will test rally.

A stock that spent years in the shadow of litigation risk has staged an extraordinary comeback, but the next chapter will be written not in courtrooms but in corporate earnings. Bayer shares have climbed roughly 72% over the past twelve months, powered by a Supreme Court ruling that undercut thousands of glyphosate claims and a growing sense that the pharmaceutical-to-agrichemical conglomerate is finally reclaiming its narrative. For now, the rally has paused for breath.

At €47.67, the stock sits about 11.5% below a 52-week high of €53.86 touched in early July. The pullback, a 6% decline over the past seven days, is widely viewed as routine profit-taking after a 30-day surge of nearly 33%. Yet the broader technical picture remains intact: the share price stands roughly 25% above its 200-day moving average of €38.10, and the relative strength index at 57.8 points to room for further gains without overheating. Annualised volatility near 62% suggests the ride will stay bumpy.

Against that backdrop, Barclays has thrown its weight behind the recovery. Analyst Charles Pitman-King raised the price target from €50 to €60 on 14 July, maintaining an “Overweight” rating. The upgrade hinges on a reassessment of US legal exposure. Late June saw the Supreme Court weaken the legal foundation for mass tort claims, and while final settlement approval is still pending, Barclays argues the risk-reward profile has shifted decisively. The bank also points to improving conditions in crop science for the second half of the year — a nod to Bayer’s largest division.

The company itself has entered a quiet period ahead of its half-year results on 4 August, during which management refrains from commenting on business developments. Attention will focus on debt reduction progress, free cash flow, and the financial impact of a recent minority stake sale to Apollo in the long-acting contraception business. On the operational front, a licensing deal with RAGT to commercialise hybrid wheat by the early 2030s signals that Bayer is investing for growth rather than merely managing litigation.

What has changed most is the market’s willingness to look beyond the legal fog. For years, every promising quarterly result was drowned out by the noise of pending trials. Now the conversation is shifting toward earnings power, strategic execution, and the three-pronged portfolio of pharmaceuticals, consumer health, and crop science. New US dollar bonds have helped stabilise the capital structure, and at a market capitalisation of €48.3 billion, Bayer remains a heavyweight in the German blue-chip index.

The path to the €60 target implies roughly 25% upside, and the record high of €53.86 — from which the stock is 11.6% away — provides a near-term milestone. But the half-year report will be the real test. Investors want to see whether the improving legal backdrop is translating into stronger operating metrics, or whether the rally has run ahead of the fundamentals. With the quiet period now in effect, the next catalyst is already on the calendar.